VEGA DAILY

Unlock Your Best Quote
Ask VEGA Now!

August 6, 2026

VITAMIN 01

Following a prolonged decline, the Nicotinamide market has recently stabilized. Current mainstream producer quotations are around USD 5.15–5.30/KG, while channel transactions remain slightly lower. The price of 3-methylpyridine has recently corrected slightly, and the acceptance of higher-priced new orders is still progressing. The short-term market is expected to remain weak but stable, with attention focused on raw material costs and downstream demand recovery.

AMINO ACID 02

Isoleucine prices have rebounded over the past two weeks, with market transactions increasing to USD 2.90–3.10/KG. Downstream purchasing interest has improved, and inquiries have become more active. Since early August, several producers have suspended quotations. In addition, Meihua Group's Tongliao production base has entered maintenance, while Heilongjiang Nuopu Biotechnology Co., Ltd., a wholly owned subsidiary of Dalian Innobio Co., Ltd., will also conduct a 2–3 week maintenance shutdown this month. With tighter spot supply and strong third-quarter order performance, producers are showing stronger price support intentions. The market is expected to remain firm in the near term.

API 03

- On August 5, CSPC Pharmaceutical Group announced the establishment of a joint venture with AstraZeneca to build a next-generation biologics manufacturing base. The partnership will integrate CSPC's AI-driven GMP manufacturing capabilities with AstraZeneca's global quality and supply chain expertise to strengthen biologics production capacity.
- Meanwhile, Lukang Pharmaceutical plans to invest approximately USD 54.81 million in a green biomanufacturing project and USD 28.74 million in a continuous intelligent API manufacturing project, aiming to accelerate synthetic biology commercialization, expand API capacity, and enhance integrated production capabilities.

FOOD ADDITIVE 04

Recently, NewPro Bioworks announced the completion of a tens-of-millions RMB Pre-A financing round (approximately several million USD), jointly led by Shanghai Guotou Xiandao and Aochuang Venture Capital Fund. The funding will mainly support the regulatory approval process for its core product lactoferrin as a new food ingredient in China, expand overseas commercialization of FDA Self-GRAS certified products, and accelerate large-scale production capacity development for functional food proteins.

Reported by Candice, Shea and Sharon